REMARKS

Claims 1-4, 36 and 39 are pending and new claims 51-55 have been added. Claims 5-35, 37-38, and 40-50 have been cancelled without prejudice or disclaimer, as drawn to non-elected inventions. Support for new claim 51 can be found e.g. on page 122, lines 20-21. Support for new claims 52-55 can be found e.g. on page 123, lines 6-9. No new matter is added.

The amendment to the claims was made to add a linking claim that permits joinder of claims relating to the making of a novel product or the use of a novel composition with the method of making the product or using the composition. In the present case, the linking claims use the novel nucleic acids of the invention with the new claims in a method of making the polypeptides of Group 2.

CONCLUSION

On the basis of the foregoing amendment and remarks, Applicants respectfully submit, that the pending claims are in condition for allowance. If there are any questions regarding this amendment and remark, the Examiner is encouraged to contact the undersigned at the telephone number provided below.

Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,529
Attorney for Applicants
c/o MINTZ, LEVIN
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

Date: August 6, 2002

Version With Markings to Show Changes

In the claims:

Claims 5-35, 37-38, and 40-50 were cancelled.

1. (Amended) An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:

(a) a mature form of an amino acid sequence [selected from the group consisting] of SEQ ID NO[S]:[2,] 4[, 6, 8, 10, 12, 14, 16, 18, 21, 23, 25, 27, 29, and 31];

(b) a variant of a mature form of an amino acid sequence [selected from the group consisting] of SEQ ID NO[S]:[2,] 4, [6, 8, 10, 12, 14, 16, 18, 21, 23, 25, 27, 29, and 31,] wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of the amino acid residues from the amino acid sequence of said mature form;

(c) an amino acid sequence [selected from the group consisting] of SEQ ID NO[S]:[2,] 4[, 6, 8, 10, 12, 14, 16, 18, 21, 23, 25, 27, 29, and 31]; and

(d) a variant of an amino acid sequence [selected from the group consisting] of SEQ ID NO[S]:[2,] 4, [6, 8, 10, 12, 14, 16, 18, 21, 23, 25, 27, 29, and 31,] wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of amino acid residues from said amino acid sequence.

2 (Amended) The polypeptide of claim 1, wherein said polypeptide comprises the amino acid sequence of a naturally-occurring allelic variant of an amino acid sequence [selected from the group consisting] of SEQ ID NO[S]:[2,] 4[, 6, 8, 10, 12, 14, 16, 18, 21, 23, 25, 27, 29, and 31].

3. (Amended) The polypeptide of claim 2, wherein said allelic variant comprises an amino acid sequence that is the translation of a nucleic acid sequence differing by a single nucleotide from a nucleic acid sequence [selected from the group consisting] of SEQ ID NO[S]:[1,] 3[, 5, 7, 9, 11, 13, 15, 17, 19, 20, 22, 24, 26, 28, and 30].

--51. (New) A method of producing the polypeptide of claim 1, the method comprising culturing a cell under conditions that lead to expression of the polypeptide, wherein said cell comprises a vector comprising an isolated nucleic acid molecule of SEQ ID NO: 3.

52. (New) The method of claim 51 wherein the cell is a bacterial cell.

53. (New) The method of claim 51 wherein the cell is an insect cell.

54. (New) The method of claim 51 wherein the cell is a yeast cell.

55. (New) The method of claim 51 wherein the cell is a mammalian cell.--

TRA 1694778v1